Do It Yourself Stock Investor

Marijuana Stocks

Marijuana stock investing has become a Canadian and U.S. interest. Stocks trade OTC, NASDAQ, NYSE and on the TSX. Marijuana stocks may be more involved in derivatives and synthetics for medicinal purposes or also encompass recreational adult use products.

Coca-Cola Preps For Marijuana Coffee

Oct. 23, 2018 | by DIYSI

Coca-Cola (NYSE: KO) has been the latest talk for the emerging marijuana sector, yet many have been getting it wrong. The activity clearly shows a focus upon CBD infused coffee not other soft drinks or alcohol alternatives. Marijuana coffee, or its derivative CBD would likely cause a relaxing drink rather than become psychoactive. This CBD-coffee causation fits Coca-Cola's ethos...

Coca-Cola's Q3 earnings report is scheduled for Tuesday, October 30th. Read more analysis on Coca-Cola Company.

Therapeutic Synthetic Marijuana Has A Green Light

Feb. 01, 2018 | by DIYSI

Conventional marijuana has not received federal approval in the United States, but synthetic derivatives have. Dronabinol is one example of a synthetic THC that is utilized for nausea and vomiting caused by cancer chemotherapy. Syndros is the brand of dronabinol produced by publicly traded, Insys Therapeutics, Inc. (NASDAQ: INSY). They are also developing a synthetic cannabidiol oral solution for child epilepsy. Their stock trades on the more regulated NASDAQ exchange, unlike many penny stock or OTC companies in the industry.

Insys Therapeutic's products are not solely in the synthetic marijuana space. They also produce opioid pain relievers and cessation treatment... go to the full analysis on Insys Therapeutics.

Canada's Neptune Brings Marijuana To NASDAQ

Jan. 10, 2018 | by DIYSI

Neptune Wellness Solutions is a Canadian based company now specializing in CBD oil extraction. Also known as Neptune (NASDAQ: NEPT), the company had been a long-standing, global producer of proprietary krill oil and other Omeg-3 products. Neptune has its factory and lab located in Quebec, Canada.

During the krill oil business, Neptune constantly spent R&D costs on defending their patents and trying to collect royalties from delinquent partners. A long dispute dragged on in Australia over Enzymotec's refusal to pay. Eventually, in April 2017 Enzymotec begain paying on their settlement of $1.63m. This was the wind-down of the Omega-3 krill war. At that time Neptune had already received a better settlement package from the more amicable, Aker BioMarine. Ultimately, Neptune sold most krill assets to Aker BioMarine for $34m. This was due to Aker's harvest fleet being a more synergetic acquirer, the best price offer, and potential future deals. Neptune also concluded that the krill oil market was too small in comparison to their opportunity in cannabidiol (CBD)... go to the full analysis on Neptune.